An update on calcineurin inhibitor-free regimens: The need persists, but the landscape has changed

Transplantation

Volumn 100, Issue 4, 2016, Pages 836-843

  Webber, Allison B ^a   Vincenti, Flavio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ASKP 1240; B7 ANTIGEN; BELATACEPT; CALCINEURIN INHIBITOR; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOSUPPRESSIVE AGENT; PROTEIN KINASE C; SOTRASTAURIN; TOCILIZUMAB; TOFACITINIB; UNCLASSIFIED DRUG; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ACUTE GRAFT REJECTION; ARTICLE; CARDIOVASCULAR DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; LYMPHOCYTE DEPLETION; MAINTENANCE THERAPY; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; ADVERSE EFFECTS; ANIMAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; ORGAN TRANSPLANTATION; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; TIME FACTOR; TREATMENT OUTCOME;

ABATACEPT; ANIMALS; CALCINEURIN INHIBITORS; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR TARGETED THERAPY; ORGAN TRANSPLANTATION; PIPERIDINES; PYRIMIDINES; PYRROLES; QUINAZOLINES; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84961891890     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000872     Document Type: Article

References (84)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4:378-383.
2. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326-2333.
3. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol. 2005;16:2234-2240.
4. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357: 2562-2575.
5. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 2002;74:1070-1076.
6. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant. 2006;6:514-522.
7. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 2001; 71:1282-1287.
8. Einecke G, Halloran PF. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure: response to Dr. Loupy et al. Am J Transplant. 2010.
9. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant. 2009;9:1063-1071.
10. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant. 2009;9:2532-2541.
11. Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the Troubled Transplant': data from the DeKAF Study. Am J Transplant. 2010.
12. Matas AJ, Leduc R, Rush D, et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN orCR: preliminary data from the DeKAF study. Am J Transplant. 2010;10: 315-323.
13. Curtis JJ. Hypertension following kidney transplantation. Am J Kidney Dis. 1994;23:471-475.
14. Curtis JJ. Hypertensinogenic mechanism of the calcineurin inhibitors. Curr Hypertens Rep. 2002;4:377-380.
15. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation. 1997;63:331-338.
16. Luke RG. Mechanism of cyclosporine-induced hypertension. Am J Hypertens. 1991;4(5 Pt 1):468-471.
17. Dew MA, DiMartini AF, De Vito Dabbs A, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation. 2007;83:858-873.
18. De Geest S, Borgermans L, Gemoets H, et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation. 1995;59: 340-347.
19. Pinsky BW, Takemoto SK, Lentine KL, et al. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant. 2009;9:2597-2606.
20. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005;331:810.
21. Tedesco Silva H Jr, Cibrik D, Johnston T et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant. 2010;10:1401-1413.
22. Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and myco-phenolate mofetil in renal allograft recipients. Am J Transplant. 2011; 11:1633-1644.
23. Langer RM, Hené R, Vitko S, et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transpl Int. 2012;25:592-602.
24. Shihab F, Qazi Y, Kaplan B, et al. Everolimus-facilitated tacrolimus minimization preserves renal function in de novo renal transplant recipients. Am J Transplant. 2014;14:538-539.
25. Havenith SH, Yong SL, van Donselaar-van der Pant KA, et al. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine-or mycophenolate-treated patients. Transplantation. 2013;95:184-191.
26. Liacini A, Seamone ME, Muruve DA, et al. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation. 2010;90:1450-1457.
27. Shihab F, Shaffer D, Qazi Y et al. Reduced incidence of CMVand BK virus infection with everolimus vs mycophenolate based regimen in de novo renal transplant recipients. Am J Transplant. 2014;14:537.
28. Boratyhska M, Watorek E, Smolska D, et al. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc. 2007;39:2736-2739.
29. Campbell SB, Walker R, Tai SS, et al. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant. 2012;12:1146-1156.
30. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367:329-339.
31. Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTor inhibitors. Transplant Rev (Orlando). 2014; 28:126-133.
32. Gao W, Lu Y, El Essawy B, et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory Tcells. Am J Transplant. 2007;7:1722-1732.
33. D'Addio F, Yuan X, Habicht A, et al. A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model. Transplantation. 2010;90:260-269.
34. Spitaler M, Cantrell DA. Protein kinaseC and beyond.Nat Immunol. 2004; 5:785-790.
35. Bigaud M, Wieczorek G, Riesen S, et al. NVP-AEB071 (AEB), a novel oral inhibitor of early T-cell activation, prolongs the survival of non-human primate (NHP) kidney allografts when used as monotherapy or at non-effective doses combined with a non-effective dose of cyclosporine (CsA). Transplantation. 2006;1:250.
36. Bigaud M, Wieczorek G, Preussing E, et al. NVP-AEB071 (AEB), the novel oral inhibitor of protein kinase C (PKC) and early T-cell activation, prolongs non-human primates (NHP) kidney allograft survival when combined with everolims (RAD), ERL080 (ERL) or FTY720 (FTY) without calcineurin inhibitor (CNI). Transplantation. 2006;1:251-252.
37. Bruns C, Pally C, Beerli C, et al. NVP-AEB071 (AEB), a novel oral inhibitor of early T-cell activation, prolongs rat cardiac allograft survival when used alone and in combination with cyclosporine, everolimusor FTY720. Transplantation. 2006;82:86(Abstract 57).
38. Wagner J, Evenou J-P, Zenke G, et al. The first-in-class oral protein kinase C (PKC) inhibitor NVP-AEB071 (AEB) prolongs renal allograft survival in non-human primates (NHP) and suppresses lymphocyte proliferation at safe exposures in human proof-of-concept studies. Transplantation. 2006;82:86.
39. Skvara H, Dawid M, Kleyn E, et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest. 2008;118:3151-3159.
40. Budde K, Sommerer C, Becker T, et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. Am J Transplant. 2010;10:571-581.
41. Friman S, Arns W, Nashan B, et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant. 2011;11:1444-1455.
42. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415-1421.
43. Podder H, Kahan BD. Janus kinase 3: a novel target for selective transplant immunosuppression. Expert Opin Ther Targets. 2004;8:613-629.
44. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875-878.
45. Buckley RH. The multiple causes of human SCID. J Clin Invest. 2004;114: 1409-1411.
46. Kaminska B, Swiatek-Machado K. Targeting signaling pathways with small molecules to treat autoimmune disorders. Expert Rev Clin Immunol. 2008;4:93-112.
47. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24:513-526.
48. Sewgobind VD, Quaedackers ME, van der Laan LJ, et al. The Jak inhibitor CP-690, 550 preserves the function of CD4CD25FoxP3 regulatory Tcells and inhibits effector T cells. Am J Transplant. 2010;10:1785-1795.
49. Borie DC, Changelian PS, Larson MJ, et al. Immunosuppression by the JAK3 inhibitor CP-690, 550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation. 2005; 79:791-801.
50. Borie DC, Larson MJ, Flores MG, et al. Combined use of the JAK3 inhibitor CP-690, 550 with mycophenolate mofetil to prevent kidney allo-graft rejection in nonhuman primates. Transplantation. 2005;80: 1756-1764.
51. Kudlacz E, Perry B, Sawyer P, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant. 2004;4:51-57.
52. Paniagua R, Si MS, Flores MG, et al. Effects of JAK3 inhibition with CP-690, 550 on immune cell populations and their functions in non-human primate recipients of kidney allografts. Transplantation. 2005;80: 1283-1292.
53. van Gurp E, Weimar W, Gaston R, et al. Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant. 2008;8:1711-1718.
54. Busque S, Leventhal J, Brennan DC, et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690, 550: a pilot study in de novo kidney allograft recipients. Am J Transplant. 2009;9: 1936-1945.
55. Vincenti F, Tedesco Silva H, Busque S, et al. Randomized phase 2b trial of tofacitinib (CP-690, 550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. 2012; 12:2446-2456.
56. Vincenti F, Silva HT, Busque S, et al. Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients. Am J Transplant. 2015;15:1644-1653.
57. Choi J, Kahwaji J, Vo A, et al. Tocilizumab (anti-IL6-receptor) therapy for donor-specific antibody (DSA plus) antibody mediated rejection (ABMR plus) resistant to IVIG plus rituxan treatment. Transplantation. 2014;98: 128-129.
58. Ford ML, Larsen CP. Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev. 2009;229:294-306.
59. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111-135.
60. Yang Y, Wilson JM. CD40 ligand-dependent Tcell activation: requirement of B7-CD28 signaling through CD40. Science. 1996;273:1862-1864.
61. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005;353: 770-781.
62. Charpentier B, Larsen C, Grinyo J, et al. Final results From the long-term extension (LTE) of the belatacept phase 2 study in kidney transplantation. Am J Transplant. 2014;14:117.
63. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10: 535-546.
64. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXTstudy). Am J Transplant. 2010;10:547-557.
65. Bray R, Gebel H, Brannon P, et al. Evaluation of donor-specific antibodies through 5 years with belatacept in BENEFIT and BENEFIT-EXT. Am J Transplant. 2014;14:117.
66. Rostaing L, Vincenti F, Grinyó J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant. 2013;13:2875-2883.
67. Soveri I, Snyder J, Holdaas H, et al. The external validation of the cardiovascular risk equation for renal transplant recipients: applications to BENEFIT and BENEFIT-EXT trials. Transplantation. 2013;95:142-147.
68. Espinosa J, Bosinger S, Farris A, et al. CD57 + CD4 Tcells and belatacept resistant rejection. Am J Transplant. 2014;14:141.
69. Ferguson R, Grinyó J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011;11:66-76.
70. Kirk AD, Guasch A, Xu H, et al. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. Am J Transplant. 2014;14:1142-1151.
71. Wojciechowski D, Chandran S, Vincenti F. Novel strategy to improve the efficacy of belatacept. Am J Transplant. 2014;14:455.
72. Elster EA, Xu H, Tadaki DK, et al. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. Transplantation. 2001;72: 1473-1478.
73. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhu-man primates. Nat Med. 1999;5:686-693.
74. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381:434-438.
75. Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6:114.
76. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus. 2004;13: 391-397.
77. Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol. 2005;174:542-550.
78. Haanstra KG, Ringers J, Sick EA, et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation. 2003;75:637-643.
79. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA. 1997;94:8789-8794.
80. Song L, Ma A, Dun H, et al. Effects of ASKP1240 combined with tacroli-mus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. Transplantation. 2014;98:267-276.
81. Goldwater R, Keirns J, Blahunka P, et al. A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects. Am J Transplant. 2013;13:1040-1046.
82. Vincenti F, Yang H, Klintmalm G, et al. Clinical outcomes in a phase 1b, randomized, double-blind, parallel group, placebo-controlled, single-dose study of ASKP1240 in de novo kidney transplantation. Am J Transplant. 2013;13:86.
83. Vanhove B, Laflamme G, Coulon F, et al. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood. 2003;102:564-570.
84. Poirier N, Dilek N, Mary C, et al. FR104, an Antagonist anti-CD28 mono-valent Fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft. Am J Transplant. 2015;15:88-100.